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Background: Some resources have suggested that genetically inactivated PTs bear a more protective effect than 
chemically inactivated products. This study aimed to produce new version of PT, by cloning an inactive PTS1 in a 
fusion form with N-terminal half of the LLO pore-forming toxin. Methods: Deposited pdb structure file of the PT 
was used to model an extra disulfide bond. Codon-optimized ORF of the PTS1 was used to make recombinant 
constructs of PTS1 and LLO-PTS1 in the pPSG-IBA35 vector. The recombinant PTS1 and LLO-PTS1 proteins were 
expressed in BL21 DE3 and SHuffle T7 strains of E. coli and purified by affinity chromatography. Cytotoxic effects 
of the recombinant proteins were examined in the MCF-7 cell line. Results: The purity of the products proved to 
be more than 85%, and the efficiency of the disulfide bond formation in SHuffle T7 strain was higher than BL21 
DE3 strain. No cytotoxicity of the recombinant proteins was observed in MCF-7 cells. Soluble recombinant PTS1 
and LLO-PTS1 proteins were produced in SHuffle T7 strain of E. coli with high efficiency of disulfide bonds 
formation. Conclusion: The LLO-PTS1 with corrected disulfide bonds was successfully expressed in E. coli SHuffle 
T7 strain. Due to the safety for human cells, this chimeric molecule can be an option to prevent pertussis disease 
if its immunostimulatory effects would be confirmed in the future. DOI: 10.29252/ibj.25.1.33 
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ertussis is a highly contagious respiratory illness 
caused by Bordetella pertussis bacteria
[1]
. This 
disease has been controlled utilizing two types 
of vaccines: the wP and aP ones
[2]
. The aP vaccines are 
subunit vaccines that contain pure and inactive 
components of B. pertussis cells
[3,4]
, including 
detoxified pertussis toxin, filamentous hemagglutinin, 
pertactin, fimbrial antigens and so on. However, the 
protectivity of the aP vaccines has not been adequate 
so that several outbreaks has been reported from 
different countries since 2012
[5,6]
. The causes of the 
weakness of aP vaccines are yet unclear because it is 
not known whether the re-emergence of pertussis is 
due to the vaccine waning immunity or to the 
fundamental differences in the nature of the immune 
response caused by aP vaccines compared with the wP 
vaccines or natural infection
[7]
. After the presentation 
of toxin-mediated theory about pertussis disease by 
Margaret Pittman in 1978
[8]
, it was suggested that a 
suitable inactivated and immunogenic PT is necessary 
P 
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and sufficient for a pertussis vaccine
[9]
. Moreover, a 
former study reported that fimbria, similar to pertactin, 
is unnecessary for vaccine-induced immuno-
stimulation
[10]
. PT is composed of two subunits: A 
subunit with ADP-ribosyltransferase activity (S1 
subunit), which is the main antigen for protection, and 
B oligomer, which is responsible for the toxin 
attachment to the target cells and is an important 
protective antigen in all available pertussis vaccines
[11]
.  
Currently, the toxoid components in aP vaccines are 
chemically inactivated by aldehyde agents. However, 
more immunogenic PTs are inactivated genetically and 
are expected to have a longer protective effect than 
current products, because of the better preservation of 
the antigenic epitopes
[9]
. The use of adjuvants in 
vaccine formulation is also important. Researchers 
believe that adjuvants can play a critical role in 
improving immunogenicity in next-generation aP 
vaccines
[12,13]
. LLO molecule has been the subject of 
many research studies, and its role as an adjuvant 
against several infection and cancer models has been 
clearly illustrated. In fact, it has been identified that 
LLO molecule can act as an adjuvant either in chimeric 
form or as a separately expressed molecule
[14-18]
.  
In this study, a new mutant of PTS1 carrying an extra 
disulfide bond was designed. This chimeric molecule 
(LLO-PTS1) was then expressed in BL21 DE3 and 
SHuffle T7 strains of E. coli and characterized further.  
 
 
MATERIALS AND METHODS 
 
The E. coli DH5α and BL21 DE3 strains were 
procured from the Pasteur Institute of Iran (Tehran). 
SHuffle®T7 competent cells were prepared from New 
England Biolabs Inc., USA. DpnI restriction enzyme 
was obtained from Thermo Fisher Scientific (USA), 
and other chemicals were provided by molecular 
biology grade providers (Sigma and Merck Co., 
Germany).  
 
Disulfide bond prediction 
1PRT.pdb file, MODIP software of the National 
Centre for Biological Sciences Integrated Web 
ServerV1.0.1
[19]
, and Disulfide By Design software 
version 2.12
[20]
 were used to model, generate files and 
analyze the new desired disulfide bond in the structure 
of the pertussis S1 enzymatic subunit. Three-






The mutant gene of PTS1 was codon-optimized and 
chemically synthesized by Pishgaman Gene Transfer 
Co. (Iran). The synthetic fragment was received in the 
pUC57 cloning vector. Mutant PTS1 used in the 
present study had the following mutations: R9K, R13L, 
and E129G. 
 
Recombinant construct preparation  
A set of primers (PerF and PerR) was applied for the 
amplification of the PTS1 gene. Each primer had a 5’ 
arm that was complementary to each side of the vector 
backbone, as illustrated in Figure 1. The PCR 
amplification of the PTS1 fragment was carried out 
using the above primers to result in PTS1 contain 










Fig. 1. Design of the mutant PTS1 cloning method. (A) For introducing the PTS1 gene into pPSG-IBA35 expression vector, two 
fragments of the multiple cloning site (blue extension) of the vector were added to the inserted gene by a simple PCR. (B) The product 
of the first PCR was used as a megaprimer in a second quick-change PCR to replace a fragment of the vector by the PTS1 gene.  
                                       First PCR                                                  Quick-change PCR 
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vector backbone. The PCR product with the size of 
about 750 bp was used in a quick-change PCR to 
synthesize the whole vector with PTS1 gene inserted 
between the two arms. Another set of primers 
employed for the amplification of LLO gene (codon 
26-266, which is N-terminally his-tagged) had already 
been sub-cloned in pPSG-IBA35. Codons of the LLO 
toxin, used in the present study, were codons 22-266. 
This part of the LLO comprised mostly of the D1 and 
D2 domains of the protein. Forward primer was 
complementary to T7 promoter. Reverse primer was 
hybridized to the last codons of N-terminal half of the 
LLO gene (up to codon 266) and had a 5' arm, which 
was complementary to the 5'-end of the PTS1 gene 
with a Gly2SerGly2 linker (Fig. 2). In addition, the 
PTS1 gene was amplified with a set of primers, at the 
forward with a 5' arm complementary to the last 
codons of LLO and the linker, and at the reverse with a 
5' arm hybridizing to the vector backbone. The PCR 
amplification of LLO and PTS1 genes with these 
primers were performed to synthesize two gene 
fragments. The fragments were fused together using a 
SOEing PCR protocol, thus leading to a PCR product 
of about 1500 bp size harboring arms complementary 
to the pPSG-IBA35 vector backbone. This PCR 
product was used in a quick-change PCR to synthesize 
the whole vector with LLO-PTS1 fusion gene inserted 
between the two arms. DpnI-treated PCR products 
were transformed into chemically competent DH5α 
bacterial cells using the heat shock method. A single 
colony from each transformation reaction was cultured 
in 5-ml LB broth containing 50 μg.mL
-1
 of ampicillin 
at 37°C for 16 hours. The recombinant plasmids were 
extracted by column method (QIAprep Spin Miniprep 
kit, Qiagen
TM
, Germany), and the sequence of the 
construct was confirmed by DNA sequencing. 
 
Recombinant protein expression and purification 
Twenty nanograms of the purified plasmids were 
used to transform BL21 DE3 and SHuffle T7 competent 
cells by the heat shock method. Multiple colonies of 
BL21 DE3 and SHuffle T7 transformants were cultured 
in a LB medium containing 50 μg.mL
-1
 of ampicillin  
at 37 °C and 28 °C, respectively, induced by the 
addition of 0.1 mM of IPTG when OD
600nm
 reached 
approximately 0.7. Expression of the recombinant 
proteins PTS1 and LLO-PTS1 was checked in a 
number of colonies. The fresh aliquots of recombinant 
protein expressing clones were used for the inoculation 
of another 100 mL of the LB medium. Clones were 
grown until the OD
600nm
 of 0.7, and the expression was 
induced by adding 0.1 mM of IPTG. After an  
overnight induction, the bacteria were harvested by 
centrifugation at 4500 ×g at room temperature for 10 
min.  Bacterial pellet was bead-beaten 15 times for 20 
seconds with a bench-top vortex with maximum 
shaking speed (2000 rpm) with 30-second intervals of 
cooling on ice. Lysis buffer contained Tris (100 mM; 
pH 8.0), NaCl (300 mM), and glycerol (10%). The 
soluble fraction was centrifuged, and the supernatant 
was loaded onto a column filled with Ni- NTA agarose 
resin (Qiagen) to purify the His-tagged recombinant 
protein. Equilibration and washing buffers of the 
chromatography were the same as the lysis buffer. 
Elution buffer was also the same as the lysis buffer, 




Fig. 2. Design of the fusion LLO-PTS1 cloning method. (A) Two gene fragments were amplified in separate PCRs and ligated 
together in a SOEing PCR protocol. (B) For introducing the LLO-PTS1 gene into pPSG-IBA35 expression vector, the product of the 







                                                     (A)                                                                      (B) 
pPSG-IBA35 
vector 
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were analyzed by 12.5%  SDS-PAGE  for the presence 
of the recombinant protein, and fractions containing the 
recombinant protein were dialyzed against the 
phosphate buffer (pH 8.0) containing 50 mM of  
NaCl. 
 
Disulfide bond determination  
Free SH groups of recombinant proteins purified 
from BL21 DE3 and SHuffle T7 E. coli strains were 
examined in a denatured condition (pre-incubating 
proteins with 6 M of GuHCl for 15 min) using 
Ellman’s reagent. Concentrations of recombinant 
protein and 5,5′-Dithiobis(2-nitrobenzoic acid) were 2 
μM and 1 mM in a cuvette of 300-μl volume, 
respectively. The absorbance of samples at 412 nm was 
measured, and the number of free SH groups was 
calculated for the recombinant PTS1 and LLO-PTS1 
proteins purified from BL21 DE3 and SHuffle T7 




Cell culture and MTT assay 
Human cell line MCF-7 was purchased from the 
Pasteur Institute of Iran (Tehran). Cells were cultured 
and maintained in RPMI-1640 medium supplemented 
with 10% FBS, streptomycin and penicillin (1%), pH 
7.4, in a humidified atmosphere of 95% air plus 5% 
CO2 at 37 °C. The anti-proliferative activity of PTS1 
and LLO-PTS1 proteins in different concentrations 
was measured by the MTT assay. Cell viability of each 
well was calculated as [A
570
 of treated cells/A
570
 of 





Disulfide bond prediction 
 The structure of the PTS1 was extracted from 
1PRT.pdb file deposited in the PDB database. After an 
energy minimization step, using the MODIP program 
and Disulfide By Design, the best disulfide bridges 
were analyzed, and one of which was selected to 
introduce into the PTS1 gene. The distance of the 
disulfide bond partners from each other in the linear 
sequence of the protein, ΔG, and dihidral bond is 
among the parameters concerned with the selection of 
the best disulfide bond. The potential disulfide bond 
selected in the present study was Phe53-Asn197 with 
the numbering of the amino acids based on the first 
methionine of the PTS1 signal sequence (Fig. 3). 
 
Fusion gene and recombinant construct preparation 
Designed PTS1 gene was chemically synthesized and 
delivered in the pUC57 cloning vector. PCR of the 
gene using primers harbouring 5’ arms complementary 
to the LLO gene fragment and the pPSG-IBA35 vector 
backbone was carried out. In addition, the 
amplification of the coding sequence of the first 241 
amino acids of LLO toxin was performed with 
designed primers. Quick-change PCR with amplified 
PTS1 gene was performed, lanes A and C in Figure 4, 
to produce recombinant construct pPSG-PTS1. 
Moreover, the SOEing PCR led to the the megaprimer 
of about 1500 bp, as illustrated in Figure 5 (lane D). 
Quick-change PCR using this megaprimer was 
conducted to produce the recombinant construct pPSG-
LLO-PTS1.  
 
Expression and purification 
Recombinant N-terminal His-tagged PTS1 protein 
and LLO-PTS1 fusion protein were produced in BL21 
DE3 and SHuffle T7 strains of E. coli in parallel using 
0.1 mM concentration of IPTG, as an inducer. The 
purity and size of the recombinant proteins produced in 
BL21 DE3 and SHuffle T7 strains were the same (lanes 
D and F; Fig. 4). Yield of the total purified protein was 
23.2 mg.L
-1
 and 13.1 mg.L
-1
 for the PTS1 protein and 
19.4 and 17.4 mg.L
-1
 for the LLO-PTS1 fusion protein 
in the two strains, respectively, after the overnight 
induction of the recombinant protein expression.  
 
Disulfide bond determination of the recombinant 
proteins 
The SH groups titration in denaturing condition 
indicated  that  the  disulfide bonds of  the recombinant 
mutant PTS1 protein purified from SHuffle T7 strain 
have been formed with high efficiency. The ratio of the 
free SH groups for each molecule was calculated, 





Fig. 3. Modeling of the new disulfide bond in the mutant 
PTS1 gene. Two amino acids, Phe53 and Asn197, were chosen 
to convert to Cys to form a new disulfide bond. Native disulfide 
bond of the PTS1 molecule is also shown. The numbering of the 
amino acids was performed concerning the Met of the signal 
sequence as the first amino acid.  
Forghani et al. LLO-PTS1 Fusion Protein and S1 Subunit of Pertussis Toxin 
 
 
Iran. Biomed. J. 25 (1): 33-40 37 
 
                                                              A        B       C                         D        E               F 
          
 
 Fig. 4. Quick-change PCR and purity of the mutant PTS1 protein. Quick-change PCR of the mutant PTS1 gene was performed using 
the whole gene as megaprimer to introduce the gene into the expression vector pPSG-IBA35. Lane A, PTS1 gene; lane B, 1 kb DNA 
size marker; lane C, quick-change PCR product; lane D, mutant PTS1 protein purified from BL21 DE3 strain; lane E, pre-stained 
protein size marker; lane F, mutant PTS1 protein purified from SHuffle T7 strain.  
 
 
purified from BL21 DE3 and SHuffle T7 strains, 
respectively. Hence, the efficiency of disulfide bond 
formation in the two proteins was approximately 80% 
and over 94%, respectively. The same results were 
procured for the LLO-PTS1 protein.  
 
Cell culture and MTT assay 
Serial dilutions of recombinant PTS1 protein and 
LLO-PTS1 fusion protein were applied to the cultured 
MCF-7 cells in RPMI 1640 media supplemented with 
10% FBS. As shown in Figure 6, the purified 
recombinant PTS1 protein was not cytotoxic to MCF-7 
cell line. The 5-fluorouracil was also tested as the 




E. coli has become the most common host for the 
recombinant protein expression. It is used readily and 
is economical. In recent years, SHuffle T7 strain of E. 
coli has been introduced for the cytoplasmic expression 
of recombinant proteins having disulfide bonds.  
It benefits from two main features: oxidative 
environment of cytoplasm and the presence of DsbC 
chaperone in the cytoplasm
[23]
. A few recombinant 
proteins have successfully been produced in SHuffle T7 
cytoplasm
[24,25]
. In the present study, recombinant 
PTS1  and  its  fusion form, LLO-PTS1, were produced  
 
                                            A         B            C         D                                   E        F 
 
 
Fig. 5. The SOEing PCR and purity of the LLO-PTS1 protein. SOEing PCR of the mutant PTS1 gene and LLO gene fragment was 
performed to produce the fusion gene for using as a megaprimer to produce the expression construct of LLO-PTS1 in pPSG-IBA35 
vector. Lanes A and B, PCR product of the amplification of the PTS1 and LLO genes; lane C, 1 kb DNA size marker; lane D, SOEing 
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Fig. 6. MCF-7 cell viability in the presence of LLO-PTS1. 
MCF-7 breast cancer cells were cultured and exposed to 
increasing concentrations of purified PTS1 and LLO-PTS1 
proteins. Independently increasing concentrations of 5-




in the SHuffle strain. Because the proteins produced in 
the present study were dialyzed in a buffer free of any 
oxidant and reducing agent after elution from the 
affinity column, it seems that the more oxidant 
environment of SHuffle T7 cytoplasm can be 
responsible for the higher efficiency of disulfide bond 
formation in the protein obtained from this strain. 
Chemically inactivated toxoid vaccines possess 
several adverse effects, thereby demanding for the use 
of alternative strategies to improve safety. Efficacy of  
the aP vaccines in generating a Th2, instead of Th1, 
immune response against pertussis antigens is also the 
matter of controversy
[26-29]
. Subunit vaccines are 
attracting interest due to the lack of native toxin 
problems. Using new subunit vaccines has been 
discussed elsewhere
[30]
. Higher stability of the subunit 
vaccines in the formulations prepared for use in 
populations in comparison with the live vaccines or 






 have found that the fusion of 
the S1, S3, and filamentous haemagglutinin can be 
expressed as a single recombinant protein. In addition, 
the produced recombinant antigen was immunogenic in 
mice, but the antibody titers against the pertussis toxin 
subunits showed to be weak. In another study, 
recombinant Mycobacterium bovis BCG was utilized 
as a host for the production of PTS1 protein. This 
mode of administration provoked a good cellular 
immunity in a mouse model, but the level of humoral 
immunity against the pertussis toxin antigen, as the 
main virulence factor of pertussis, was low
[33]
. 
Diphtheria, tetanus, and pertussis toxin molecule 
subunits have already been expressed in tobacco and 
carrot in a soluble form. It has been indicated that these 
plant-derived proteins could elicit a specific antibody 
response in animal models
[34]
. Although there are 
several advantages in large-scale protein production in 
plants over the conventional biofactories like the 
animal cell lines or yeast and bacteria cells, there are 
yet some challenges in the industrial extraction and 
purification steps. Recombinant pertussis toxin 
subunits have also been expressed and purified 
separately to form oligomers in vitro. They bear the 
potential to form in vitro assemblies, which are 
antigenic, and the antibodies they provoke have been 
displayed to have inhibitory activities against pertussis 
toxin
[35]
.   
Herein, we have produced a new form of genetically 
inactivated PTS1 using a cloning strategy, which 
successfully produced two forms of inactivated PTS1 
toxin (PTS1 and fusion LLO-PTS1 proteins) in E. coli 
BL21 DE3 and SHuffle T7 strains. However, the rate of 
the disulfide bond in SHuffle T7 strain showed to be 
more efficient. The analysis of the safety of the 
proteins produced against a cell line model revealed 
that both recombinant proteins are safe and non-toxic 
for the human cell culture model. Our results 
demonstrated that the recombinant proteins PTS1 and 
LLO-PTS1 can be expressed in SHuffle T7 strain 
cytoplasm and purified in a soluble form with disulfide 
bonds with high efficiency. Overall, the LLO-PTS1 
fusion protein can be formulated as a new generation 
of the adjuvants to be used as a novel immune-
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